Supporting policies that will promote innovation based on traditional medicine

24 scientists are provided scholarship. Co-funding are also provided for joint projects between supervisors and research institutes. For the private sector and industries,, the following incentives are provided:  Tax deduction for RD expense and depreciation cost  Ta e e ptio fo i po ted e uip e t s a d o po ate i o e ta  Cash and soft loan  Joint venture with technology transfer  Buddymentor system  Consultancy system  Services on ST In India, the Biotechnology Industry Research Advisory Council BIRAC, to date, has supported 240 companies for 360 projects with a funding support of approximately 100 million USD. From the private sector, the commitment for funding support is worth of 120 million USD. Out of these, 77 projects involved Industry-Academia collaborations which have delivered 17 affordable products and 11 new technologies creating 24 intellectual property and 3 bio-industrial facilities. 51 Drug regulation imposes standards on the products of health related research and development. It is intended to protect patients by ensuring the quality, efficacy and safety of new pharmaceuticals a d iologi al. I , a stud as o du ted fo WHO s Co issio o I telle tual p ope t Rights, Innovation and Public Health CIPIH to address the issue of the impacts of drug regulation on incentives for RD of new drugs and vaccines. It examined the ways in which regulatory framework affect the incentives for pharmaceutical innovation using ASEAN member countries as a case study. 82 Global In the area of developing antibacterial drugs, the following policies to create incentives have been proposed: 83 a. Financial incentives – tax credits; advanced market commitments for purchase; payments for conservation b. Priority review vouchers – US legislation enacted in 2007 aimed to provide an incentive to develop drugs for neglected tropical diseases by allowing the US FDA to grant companies that obtain approval for a drug for a tropical disease a one-time, transferable priority review voucher for an unrelated future drug. c. Orphan drug incentives – for example, the 1983 US Orphan Drug Act offers extended tax credits and guarantees 7 years of market exclusivity to developers of drugs for rare conditions that affect 200,000 patients in the US. The US Congress could extend the act cover all new antibacterials or enact a law specifically for antibacterials for certain multi-drug resistant infections d. Liability exemption – exempt manufacturers from liability associated with their anti- bacterials, as with the case of vaccine manufacturers